OSE Immunotherapeutics Confirms Marc Le Bozec as CEO
OSE Immunotherapeutics announces the permanent appointment of Marc Le Bozec as CEO, effective immediately. Mr. Le Bozec has been serving in this role on an interim basis since October 2, 2025.
The Board of Directors of OSE Immunotherapeutics has unanimously confirmed, upon recommendation from the Nomination and Compensation Committee, the appointment of Marc Le Bozec as the permanent CEO. This decision follows a thorough review of both internal and external candidates. Mr. Le Bozec continues from his role as interim CEO, which he has held since October 2, 2025.
Details on Compensation Policy
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The compensation policy for Marc Le Bozec in his capacity as CEO will be published in the OSE Immunotherapeutics Universal Registration Document 2025 and will be subject to the vote at the Company's Annual General Meeting, which will review the accounts for the fiscal year ending December 31, 2025.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
